CTMX Insider Trading Activity and SEC Form 4 Filings
CTMX insider trading summary
Over the past 12 months, insiders at CytomX Therapeutics, Inc. (CTMX) reported 1 sale worth $5K by 1 insider and no open-market purchases on SEC Form 4. Net insider selling was $5K.
Latest CTMX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Christopher Ogden | Chief Financial Officer | Sell | $5K (1,624 @ $3.05) |
| Nov 6, 2025 | Sean A. McCarthy | CEO | Sell | $462K (101,793 @ $4.54) |
| Nov 6, 2025 | Sean A. McCarthy | CEO | Sell | $462K (101,793 @ $4.54) |
| Jun 16, 2025 | Sean A. McCarthy | CEO | Sell | $149K (55,511 @ $2.69) |
| Jun 16, 2025 | Marcia Belvin | SVP, Chief Scientific Officer | Sell | $37K (13,884 @ $2.69) |
| Jun 16, 2025 | Christopher Ogden | Chief Financial Officer | Sell | $29K (10,614 @ $2.69) |
| Jun 13, 2025 | Christopher Ogden | Chief Financial Officer | Sell | $5K (1,641 @ $2.95) |
| Mar 18, 2025 | Christopher Ogden | Chief Financial Officer | Sell | $5K (8,551 @ $0.60) |
| Mar 18, 2025 | Sean A. McCarthy | CEO | Sell | $23K (37,656 @ $0.60) |
| Mar 18, 2025 | Yu-Waye Chu | Chief Medical Officer | Sell | $2K (4,025 @ $0.60) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.